IMF Videos Search Content For Healthcare Professional (132) Healthcare Provider (132) Care Partner (67) Patient (67) Series - Any - ASCO/EHA (51) ASH (69) Ask Dr. Durie (23) Black Swan Research Initiative (2) Emerging Therapies (3) Facebook Live (6) IMWG (4) Living Well with Myeloma (2) Myeloma in a Minute (5) Myeloma Made Simple (5) Myeloma University (4) Patient & Family Webinar (1) Q&A (11) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (68) High-Risk Myeloma (45) High-risk Smoldering Myeloma (38) Late Relapse (4–6 Lines of Therapy) (84) MGUS (39) Newly Diagnosed (Pre-Treatment or First Treatment) (63) Smoldering Myeloma (49) Types of Therapy Immunomodulatory drugs (IMiDs) (60) Immunotherapies (CAR T; BiTE, etc.) (100) Monoclonal antibodies (54) Proteasome inhibitors (46) Stem cell transplant (38) Steroids (42) Supportive Care (43) Year Published 2026 (20) 2025 (32) 2024 (52) 2023 (43) 2022 (17) 2021 (12) 2020 (1) 2019 (10) 2018 (2) 2017 (1) 2016 (2) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (20) Dr. María-Victoria Mateos (7) Dr. Saad Usmani (3) Dr. Shaji Kumar (2) Dr. Sigurður Kristinsson (2) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (1) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse January 11, 2024 ASH Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial January 8, 2024 ASH Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study January 8, 2024 ASH Iceland’s iStopMM Study Revises Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance (MGUS) January 8, 2024 ASH The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B) January 8, 2024 ASH The STEM Trial Phase II Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy January 8, 2024 ASH Updates in Myeloma Treatment: BMS-986393 CAR T-Cell Therapy Shows Promise in Phase I Study for Relapsed/Refractory Patients January 8, 2024 ASH Optimizing Myeloma Treatment: Pomalidomide-based Regimens Compared in Asian Myeloma Network (AMN) Study — a Phase III Analysis of PCd vs. Pd for Relapse or Refractory Myeloma (RRMM) January 4, 2024 ASH What is the IMF's iStopMM study? December 7, 2023 Ask Dr. Durie How is the Black Swan Research Initiative Approaching Early Myeloma Development? November 30, 2023 Ask Dr. Durie What is the IMF's Asian Myeloma Network? | Enhancing myeloma care in Asia and globally. October 26, 2023 Ask Dr. Durie Ask Me Anything Replay: Exploring Myeloma Research Breakthroughs with Dr. Joseph Mikhael October 23, 2023 Facebook Live Load More
